A new first-of-its-kind study will assess Zika virus as a tool to target glioblastomas, one of the most challenging cancers to treat.
The European Commission has approved dinutuximab beta for the treatment of high-risk neuroblastoma patients over the age of 12 months, making it the only approved immunotherapy for these patients in Europe.
The article reviews current literature on the use of adoptive immunotherapy for malignant gliomas as well as the
the concept of antitumor activity mediated by CIK cells.
A large, multicenter, genome-wide association study has identified a number of new genetic risk loci for malignant brain tumors.
Researchers have identified novel genetic errors associated with an increased risk of developing glioma, in the largest ever study of the disease.
Karmakar & Reilly review what is known about the role of NF1 mutation in immune cell function & the role of immune cells in promoting tumorigenesis in NF1.
New research has elucidated a pathway in diffuse intrinsic pontine glioma with promise for therapeutic targeting.
Immunotherapy for glioblastoma has been an area of intense research in recent years – this review looks at the potential of HCMV in the initiation, promotion and progression of tumorigenesis.
For the first time, researchers describe the pathological features of a severe liver-injury associated with the administration of the anti–PD-1 agent nivolumab in a patient with glioblastoma.
Christian Naus discusses his work on 3D glioma models, which could facilitate personalized medicine approaches to one of the brain’s most significant threats.